Thomas Hwang, MD @thomasmd · Sep 8, 2023, Sep 8, 2023, 11:47 AM new piece @JAMAOnc on new therapies for BCG-unresponsive NMIBC and modernizing FDA guidance on trial design. @MA_Preston @daviesbj jamanetwork.com/journals/jamao…
Thomas Hwang, MD @thomasmd · Feb 21, 2023, Feb 21, 2023, 3:11 PM Thank you @Nature @maxdkozlov for covering our NEJM piece and the new law on diversity in clinical trials. Looking forward to presenting at Multi-Disciplinary conference @DanaFarber_GU and discussing implications for trialists.nature.com/articles/d4158…
Thomas Hwang, MD @thomasmd · Oct 10, 2022, Oct 10, 2022, 9:33 PM Thanks @Nicole_DeFeudis for talking with me about our NEJM piece and proposed framework to ensure more representative clinical trials. in @endpts endpts.com/are-incentives… endpoints.news Are incentives necessary to achieve trial diversity? Two researchers say yes Pharma companies and even Congress have made efforts over the last year to ensure clinical trials are more representative of the patients they serve — but two researchers argue that isn’t ...
Thomas Hwang, MD @thomasmd · Sep 30, 2022, Sep 30, 2022, 7:21 PM Thank you @cecelou18 for talking with me in Bloomberg on reforms to accelerated approval; earlier in @Medscape @endpts (more in recent work @TheLancet @JAMAHealthForum)news.bloomberglaw.com/health-law-and… news.bloomberglaw.com Biogen’s Next Alzheimer Drug Feeds Push for FDA Approval Revamp Promising trial results on Eisai Co. and Biogen Inc.‘s Alzheimer’s drug don’t discount the need for changes to the fast-track approval pathway the FDA is using to review the product, doctors and...
Thomas Hwang, MD @thomasmd · Aug 19, 2022, Aug 19, 2022, 11:42 PM Thanks Jeannie @bloomberglaw for talking with me about our study in @JAMAHealthForum@KNVokinger news.bloomberglaw.com/pharma-and-lif… news.bloomberglaw.com More Than Half of Fast-Tracked Drugs Fail to Offer High Value Most fast-tracked drug approvals by US and European regulators fail to provide high therapeutic value, in a study researchers say underscores the need for stronger government oversight.